HSDT
Solana Company · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-31
Figures on this page computed 2026-11-08 12:40 UTC
Last close
2.10USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-31
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-31
-83.0%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
-679.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
0.00Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Margins is the furthest below its sector's middle: 0.36 against 0.40 on the market's range.
- Growth55.5%52 of 100, above its sector
- Returns on capital-83.0%21 of 100, below its sector
- Margins91.7%36 of 100, below its sector
- Price0.1x55 of 100, above its sector
- Safety0.0096 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 1 of 3- Profit on each unit of sales-680%-135%Behind
Higher is better here.
- Return on the capital it uses-83.0%n/an/a
Higher is better here.
- Sales growth over five years55.5%4.8%Ahead
Higher is better here.
- Debt against equityn/a0.10n/a
Lower is better here.
- Gross margin91.7%81.2%Ahead
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against MaxCyte, Inc., HSDT is behind on 1 of 3 measures.
Against MaxCyte, Inc., HSDT is behind on 1 of 3 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-31
Profit on each unit of sales-679.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
Return on the capital it uses-83.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
Sales growth over five years55.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
Debt against equityn/a
The stored value is a zero that stands for missing data rather than a measurement, so we will not place it.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
Gross margin91.7%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037194
- Reported in
- USD